The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | Strategies to overcome resistance to HMAs
In this video, Harinder Gill, MBBS, PDipID, MD, MRCP, FRCP, FRCPath, FHKCP, FHKAM, The University of Hong Kong, Hong Kong, China discusses the mechanisms of resistance to hypomethylating agents (HMA) and the several strategies available to overcome this resistance. For example, Dr Gill describes how IDH1 or IDH2 mutations may confer resistance and how these mutations may be targeted with ivosidenib. Dr Gill also comments on immune dysregulation MDS and highlights the potential of targeting TIM-3 with monoclonal antibodies such as sabatolimab. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Novartis Oncology – honoraria, consultancies; Celgene/bms – research grant, honoraria, consultancies; PharmaEssentia – research grant; Abbvie – honoraria, consultancies; Takeda – honoraria; Pfizer Oncology – honoraria, consultant
